Center for Modular Manufacturing of Structural Tissues
结构组织模块化制造中心
基本信息
- 批准号:10554848
- 负责人:
- 金额:$ 106.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-06-01 至 2027-05-31
- 项目状态:未结题
- 来源:
- 关键词:AdoptionAnimal TestingAppearanceAutomationBasic ScienceBiologicalBiological ProductsBiomedical EngineeringBioreactorsBiosensing TechniquesCartilageCell Culture TechniquesCell physiologyCellsCessation of lifeCharacteristicsClinicalCollaborationsCommunitiesCommunity DevelopmentsConditioned Culture MediaCongenital AbnormalityData Management ResourcesDevelopmentDiseaseDrug ScreeningEngineeringEnsureEvaluationEvolutionFeedbackFeedsFundingGenerationsGoalsGrowthIndividualInstitute of Medicine (U.S.)InstitutesInstructionInterventionKnowledgeLaboratoriesMechanical StimulationMedicalMethodsModelingMolecularMonitorPathway interactionsPatientsPharmacologic SubstancePhenotypeProcessPropertyProtocols documentationPublicationsQuality ControlRegenerative MedicineReporterResourcesRiskRunningScienceServicesSite-Directed MutagenesisSystemTechnologyTestingTimeTissue EngineeringTissue constructsTissuesTrainingTraumaVertebral columnbasebiomedical imagingbridge programcohesioncost effectivedesignexperienceflexibilityimprovedinnovationinnovative technologiesinsightmanufacturing processmanufacturing process developmentmeetingsmultimodalitynew technologynon-invasive monitornoveloptical sensorpersonalized medicinepreventproduct developmentprogram disseminationprogramsprototyperegenerativeresearch and developmentscaffoldsensorsuccesssymposiumtooluser-friendlyweb site
项目摘要
Despite significant advances over several decades, very few Tissue Engineered Medical Products (TEMPs) have
been clinically or commercially successful, as a significant technology gap, known as the “Valley of Death”, has
prevented their scalable, consistent and cost-effective manufacture. This proposal is for the competing renewal
of the current “Case Center for Multimodal Evaluation of Engineered Cartilage.” There is a growing need for
TEMPs in multiple applications. We therefore believe that now is the time for a bold shift from our original focus
on cartilage-centric evaluation technologies to developing, demonstrating, and deploying novel technologies to
enable Quality-by-Design manufacturing of a variety of structural tissues, and to, thus, bridge the Valley of Death.
The goal of the Center is the adoption of our technologies by the TEMP community at large. Consequently, the
Center, will be renamed “Center for Modular Manufacturing of Structural Tissues” (CM2OST), and will apply
knowledge and technology developed during the first 5 years to manufacturing-oriented challenges. The Center
will be a consortium between CWRU and the Advanced Regenerative Manufacturing Institute (ARMI), and will
focus on technologies that enable scalable, modular, automated, closed (SMAC) manufacturing. The Specific
Aims of the proposal are to 1) Assist our CPs and SPs by pushing the technologies developed at the Center
out to them. 2) Develop a cohesive set of innovative technologies, methods, and protocols that enable
structural tissue manufacturing through 4 TR&D projects, described below, and 3) Develop a new, state-of-the-
art, training and dissemination program. Strategically, we will break the overall R&D program into 4 TR&Ds
representing key components of the TEMP assembly-line model. TR&D-1 covers dynamic control of cell pheno-
type and function during the manufacturing process, and development of tissue-specific sensors for dynamic
non-invasive monitoring of cell phenotype and function. TR&D-2 will develop sensor-enabled scaffolds and novel
optode-based optical sensors to automate cell seeding and to monitor metabolites and provide feedback on local
and bulk medium conditions. TR&D-3 will develop bio-instructive bioreactors with integrated actuators and sen-
sors for feedback control, and will physically integrate them with the Tissue Foundry, an ARMI prototype auto-
mated TEMP assembly line. TR&D-4 will integrate sensors and actuators with the automation and data man-
agement system of the Tissue Foundry and will perform a manufacturing demonstration run. Demonstrating
technologies developed in the TR&Ds will provide insights into TEMP development, process development and
automation, and expose unanticipated technology gaps. Each TR&D represents a step in the TEMP assembly-
line model, thus, though the technologies are developed independently, each TR&D feeds into the next. TR&Ds,
Collaborative and Service Projects synergize, integrating and exploiting each other’s technologies as they come
online. CM2OST will be a national resource for collaborations and a platform for developing, testing, validating,
and disseminating new technology, methods, and protocols for TEMP manufacturing.
尽管几十年来取得了重大进展,但很少有组织工程医疗产品(TEMPs)
在临床上或商业上取得了成功,因为一个重大的技术差距,被称为“死亡谷”,
阻碍了它们的可扩展、一致和具有成本效益的制造。这份提案是为了
“工程车辆多模式评估案例中心”。越来越需要
多个应用程序中的临时协议。因此,我们认为,现在是大胆地改变我们原来的重点的时候了
以软骨为中心的评估技术,以开发,演示和部署新技术,
使各种结构组织的质量设计制造成为可能,从而架起死亡之谷的桥梁。
该中心的目标是通过我们的技术在整个TEMP社区。因此
中心,将更名为“结构组织模块化制造中心”(CM 2 OST),并将适用于
知识和技术的发展在第一个5年,以制造为导向的挑战。中心
将由CWRU和高级再生制造研究所(ARMI)组成的联盟,并将
专注于实现可扩展、模块化、自动化、封闭(SMAC)制造的技术。具体
该提案的目的是:1)通过推动中心开发的技术来帮助我们的CP和SP
给他们。2)开发一套有凝聚力的创新技术、方法和协议,
结构组织制造,通过4个TR&D项目,如下所述,和3)开发一个新的,国家的-
艺术、培训和传播方案。在战略上,我们将把整个研发计划分解为4个TR& D
代表TEMP装配线模型的关键组件。TR&D-1涵盖细胞表型的动态控制,
制造过程中的类型和功能,以及用于动态的组织特异性传感器的开发
细胞表型和功能的非侵入性监测。TR&D-2将开发传感器支架和新型
基于光电二极管的光学传感器,用于自动化细胞接种和监测代谢物,并提供局部反馈。
和散装介质条件。TR&D-3将开发具有集成执行器和传感器的生物指导生物反应器,
传感器的反馈控制,并将物理集成他们与组织铸造,一个ARMI原型自动,
配套TEMP装配线。TR&D-4将把传感器和执行器与自动化和数据人集成在一起,
组织铸造系统,并将进行生产示范运行。展示
在技术研究与开发计划中开发的技术将为技术环境管理计划的开发、工艺开发和
自动化,并暴露出意想不到的技术差距。每个TR&D代表TEMP组件中的一个步骤-
因此,尽管技术是独立开发的,但每个TR&D都是下一个TR&D的补充。TR& D,
协作和服务项目协同、集成和利用彼此的技术
网上CM 2 OST将成为国家合作资源和开发、测试、验证
推广TEMP制造的新技术、新方法和新协议。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arnold Irwin Caplan其他文献
Arnold Irwin Caplan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arnold Irwin Caplan', 18)}}的其他基金
Administrative Supplement to CWRU Center for Multimodal Evaluation of Engineered Cartilage
CWRU 工程软骨多模式评估中心的行政补充
- 批准号:
10468459 - 财政年份:2021
- 资助金额:
$ 106.37万 - 项目类别:
Role of Perivascular Mesenchymal Stem Cells (pMSCs) in the Bone Marrow Niche and the Extracellular Matrix in the Control of Skeletal Metastasis
骨髓微环境中血管周围间充质干细胞 (pMSC) 和细胞外基质在控制骨骼转移中的作用
- 批准号:
10413249 - 财政年份:2020
- 资助金额:
$ 106.37万 - 项目类别:
Role of Perivascular Mesenchymal Stem Cells (pMSCs) in the Bone Marrow Niche and the Extracellular Matrix in the Control of Skeletal Metastasis
骨髓微环境中血管周围间充质干细胞 (pMSC) 和细胞外基质在控制骨骼转移中的作用
- 批准号:
10028072 - 财政年份:2020
- 资助金额:
$ 106.37万 - 项目类别:
Role of Perivascular Mesenchymal Stem Cells (pMSCs) in the Bone Marrow Niche and the Extracellular Matrix in the Control of Skeletal Metastasis
骨髓微环境中血管周围间充质干细胞 (pMSC) 和细胞外基质在控制骨骼转移中的作用
- 批准号:
10248515 - 财政年份:2020
- 资助金额:
$ 106.37万 - 项目类别:
CWRU Center for Multimodal Evaluation of Engineered Cartilage
CWRU 工程软骨多模式评估中心
- 批准号:
9072578 - 财政年份:2016
- 资助金额:
$ 106.37万 - 项目类别:
CWRU Center for Multimodal Evaluation of Engineered Cartilage
CWRU 工程软骨多模式评估中心
- 批准号:
9895783 - 财政年份:2016
- 资助金额:
$ 106.37万 - 项目类别:
CWRU Center for Multimodal Evaluation of Engineered Cartilage
CWRU 工程软骨多模式评估中心
- 批准号:
8890431 - 财政年份:2014
- 资助金额:
$ 106.37万 - 项目类别:
CWRU Center for Multimodal Evaluation of Engineered Cartilage
CWRU 工程软骨多模式评估中心
- 批准号:
8901167 - 财政年份:2014
- 资助金额:
$ 106.37万 - 项目类别:
相似海外基金
Bioreactors to Replace Animal Testing in Bone Research
生物反应器取代骨骼研究中的动物测试
- 批准号:
NC/Y500562/1 - 财政年份:2024
- 资助金额:
$ 106.37万 - 项目类别:
Training Grant
Animal testing of RNA aptamers as ALS drug candidate
RNA适体作为ALS候选药物的动物试验
- 批准号:
10453877 - 财政年份:2022
- 资助金额:
$ 106.37万 - 项目类别:
Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity
用于伴侣动物测试的两种 SARS-CoV-2 检测的实施和评估,以扩大 Vet-LIRN COVID-19 能力
- 批准号:
10665685 - 财政年份:2022
- 资助金额:
$ 106.37万 - 项目类别:
Implementation and Evaluation of Two SARS-CoV-2 Assays for Companion Animal Testing to Expand Vet-LIRN COVID-19 Capacity
用于伴侣动物测试的两种 SARS-CoV-2 检测的实施和评估,以扩大 Vet-LIRN COVID-19 能力
- 批准号:
10609646 - 财政年份:2022
- 资助金额:
$ 106.37万 - 项目类别:
Animal testing of RNA aptamers as ALS drug candidate
RNA适体作为ALS候选药物的动物试验
- 批准号:
10646463 - 财政年份:2022
- 资助金额:
$ 106.37万 - 项目类别:
Data mining tool to build database to reduce animal testing in drug development.
数据挖掘工具建立数据库以减少药物开发中的动物试验。
- 批准号:
10042916 - 财政年份:2022
- 资助金额:
$ 106.37万 - 项目类别:
Grant for R&D
AgroPathogenMeter- developing a handheld platform for on-farm, rapid and, inexpensive animal testing
AgroPathogenMeter - 开发用于农场快速且廉价的动物测试的手持平台
- 批准号:
506300-2017 - 财政年份:2019
- 资助金额:
$ 106.37万 - 项目类别:
Strategic Projects - Group
Development of a novel alternative to animal testing for the evaluation of respiratory allergic sensitizing potential of chemicals
开发一种新的动物试验替代方案,用于评估化学品的呼吸道过敏致敏潜力
- 批准号:
18K11658 - 财政年份:2018
- 资助金额:
$ 106.37万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the feasibility of adapting a direct PCR diagnostics approach to in-field animal testing
研究将直接 PCR 诊断方法应用于现场动物测试的可行性
- 批准号:
104623 - 财政年份:2018
- 资助金额:
$ 106.37万 - 项目类别:
Collaborative R&D














{{item.name}}会员




